Skip to main
TVTX

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 40%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics is expected to report strong results in the second quarter of 2026, with total revenue of $170 million beating both consensus and Wall Street estimates. Despite an initial loss due to a convertible note expense, the company has a strong cash position and a promising pipeline candidate in sparsentan, making it a valuable investment with potential for significant growth. Additionally, the company's recent patent extension for Filspari in the IgAN indication provides added exclusivity until 2037, increasing the stock's target price to $75. The impending FDA alignment for pegtibatinase and the potential for Filspari to work in conjunction with newer agents in the market also lend additional support to the company's position. However, potential delays or setbacks in commercializing their products, as well as the need for future capital raises, are potential risks to consider when investing in Travere Therapeutics.

Bears say

Travere Therapeutics is a biopharmaceutical company with a focus on developing therapies for rare kidney, liver, and metabolic diseases. Despite strong initial momentum following the launch of Filspari for FSGS, the latest quarterly figures showed a significant slowdown in patient start forms, potentially indicating a potential slowdown in demand. Additionally, the company's increased SG&A expenses and continued reliance on a single product for revenue make us cautious about its long-term prospects.

Travere Therapeutics (TVTX) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 40% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 10 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $66.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $66.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.